Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2618 with Demethylation Drugs in R/R AML and MDS
NCT05426798Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2022
- Primary completion
- Sep 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2618 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 78 weeks, Dose Limited Toxicity at 78 weeks and 2 more. Status: unknown.
02
Drugs
TQB2618
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05426798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05426798.